News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
378,440 Results
Type
Article (12495)
Company Profile (55)
Press Release (365890)
Multimedia
Podcasts (26)
Webinars (9)
Section
Business (117457)
Career Advice (757)
Deals (21628)
Drug Delivery (54)
Drug Development (30254)
Employer Resources (70)
FDA (8925)
Job Trends (8258)
News (182090)
Policy (16230)
Tag
Academia (961)
Accelerated approval (3)
Adcomms (5)
Allergies (42)
Alliances (26148)
ALS (34)
Alzheimer's disease (556)
Antibody-drug conjugate (ADC) (46)
Approvals (8989)
Artificial intelligence (187)
Autoimmune disease (10)
Automation (8)
Bankruptcy (151)
Best Places to Work (6855)
BIOSECURE Act (7)
Biosimilars (62)
Biotechnology (39)
Bladder cancer (40)
Brain cancer (12)
Breast cancer (147)
Cancer (1079)
Cardiovascular disease (91)
Career advice (665)
Career pathing (10)
CAR-T (58)
Cell therapy (193)
Cervical cancer (10)
Clinical research (25535)
Collaboration (439)
Compensation (207)
Complete response letters (7)
COVID-19 (1050)
CRISPR (19)
C-suite (180)
Cystic fibrosis (37)
Data (1173)
Decentralized trials (2)
Denatured (10)
Depression (19)
Diabetes (140)
Diagnostics (4276)
Digital health (12)
Diversity (4)
Diversity, equity & inclusion (21)
Drug discovery (47)
Drug pricing (56)
Drug shortages (7)
Duchenne muscular dystrophy (59)
Earnings (51205)
Editorial (23)
Employer branding (10)
Employer resources (65)
Events (71706)
Executive appointments (534)
FDA (9842)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (5)
Funding (424)
Gene editing (41)
Generative AI (22)
Gene therapy (134)
GLP-1 (296)
Government (2124)
Grass and pollen (2)
Guidances (131)
Healthcare (11908)
Huntington's disease (4)
IgA nephropathy (15)
Immunology and inflammation (39)
Indications (18)
Infectious disease (1127)
Inflammatory bowel disease (60)
Inflation Reduction Act (7)
Influenza (26)
Intellectual property (39)
Interviews (93)
IPO (10235)
IRA (18)
Job creations (1691)
Job search strategy (594)
Kidney cancer (8)
Labor market (11)
Layoffs (209)
Leadership (13)
Legal (3684)
Liver cancer (39)
Lung cancer (152)
Lymphoma (83)
Machine learning (3)
Management (24)
Manufacturing (135)
MASH (47)
Medical device (8308)
Medtech (8309)
Mergers & acquisitions (11803)
Metabolic disorders (358)
Multiple sclerosis (47)
NASH (11)
Neurodegenerative disease (31)
Neuropsychiatric disorders (9)
Neuroscience (788)
NextGen: Class of 2025 (3941)
Non-profit (2269)
Now hiring (5)
Obesity (176)
Opinion (105)
Ovarian cancer (39)
Pain (39)
Pancreatic cancer (32)
Parkinson's disease (54)
Partnered (11)
Patents (72)
Patient recruitment (62)
Peanut (25)
People (35507)
Pharmaceutical (16)
Pharmacy benefit managers (10)
Phase I (6886)
Phase II (10394)
Phase III (10049)
Pipeline (1001)
Policy (65)
Postmarket research (1170)
Preclinical (2516)
Press Release (67)
Prostate cancer (50)
Psychedelics (9)
Radiopharmaceuticals (155)
Rare diseases (194)
Real estate (2908)
Recruiting (27)
Regulatory (11601)
Reports (22)
Research institute (886)
Resumes & cover letters (97)
Rett syndrome (6)
RNA editing (1)
RSV (20)
Schizophrenia (35)
Series A (64)
Series B (55)
Service/supplier (3)
Sickle cell disease (28)
Special edition (7)
Spinal muscular atrophy (79)
Sponsored (11)
Startups (1902)
Stomach cancer (4)
Supply chain (31)
Tariffs (21)
The Weekly (16)
Vaccines (250)
Venture capitalists (21)
Weight loss (86)
Women's health (23)
Worklife (9)
Date
Today (139)
Last 7 days (574)
Last 30 days (1874)
Last 365 days (18773)
2025 (7353)
2024 (20291)
2023 (22962)
2022 (31779)
2021 (34189)
2020 (33530)
2019 (27127)
2018 (20483)
2017 (16961)
2016 (16331)
2015 (19991)
2014 (15386)
2013 (12571)
2012 (13329)
2011 (13731)
2010 (12607)
Location
Africa (380)
Alabama (26)
Alaska (3)
Arizona (111)
Arkansas (7)
Asia (19806)
Australia (2788)
California (3620)
Canada (1205)
China (253)
Colorado (171)
Connecticut (166)
Delaware (89)
Europe (45026)
Florida (560)
Georgia (119)
Hawaii (1)
Idaho (38)
Illinois (326)
India (21)
Indiana (197)
Iowa (3)
Japan (130)
Kansas (46)
Kentucky (18)
Louisiana (9)
Maine (64)
Maryland (474)
Massachusetts (2804)
Michigan (142)
Minnesota (247)
Mississippi (2)
Missouri (65)
Montana (20)
Nebraska (17)
Nevada (41)
New Hampshire (35)
New Jersey (1211)
New Mexico (10)
New York (1052)
North Carolina (677)
North Dakota (4)
Northern California (1685)
Ohio (111)
Oklahoma (9)
Oregon (14)
Pennsylvania (819)
Puerto Rico (4)
Rhode Island (15)
South America (541)
South Carolina (14)
Southern California (1343)
Tennessee (80)
Texas (448)
United States (14084)
Utah (150)
Virginia (83)
Washington D.C. (38)
Washington State (308)
West Virginia (3)
Wisconsin (46)
378,440 Results for "priority healthcare corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Rare diseases
Priority Review Vouchers: By the Numbers
A
BioSpace
analysis of all 80 priority review vouchers that have been handed out across the three FDA programs that offer them found that 2024 was the busiest year yet. Companies have disclosed spending $513 million on vouchers that were earned in 2024 so far.
March 5, 2025
·
1 min read
·
Annalee Armstrong
Editorial
This Might Be a Moot Point but the FDA’s Priority Review Vouchers Need Transparency
While Congress is renewing the priority review voucher program for rare pediatric diseases, the FDA should be required to keep public records of the passes changing hands, too.
March 7, 2025
·
3 min read
·
Annalee Armstrong
Rare diseases
Rare Disease Biotechs Left in a Lurch as Congress Fails To Renew Priority Review Program
Congress did not reauthorize the rare pediatric disease priority review program at the end of 2024. Advocates say the ripple effect is already being felt across biopharma.
March 5, 2025
·
9 min read
·
Annalee Armstrong
Press Releases
Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025
January 13, 2025
·
8 min read
Press Releases
CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update
January 7, 2025
·
10 min read
Press Releases
Healthcare Integrated Technologies Inc. Announces Corporate Name Change to SafeSpace Global Corporation and Ticker Symbol Update
April 24, 2025
·
2 min read
Press Releases
Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
January 13, 2025
·
22 min read
Press Releases
Day One Reports Preliminary 2024 OJEMDA™ Net Product Revenue and Highlights 2025 Corporate Priorities
January 13, 2025
·
6 min read
Press Releases
Atea Pharmaceuticals to Highlight 2025 Strategic Priorities at the 43rd Annual J.P. Morgan Healthcare Conference
January 14, 2025
·
9 min read
Press Releases
InnoCare’s Zurletrectinib Receives Priority Review from China’s NMPA
May 2, 2025
·
2 min read
1 of 37,844
Next
